Loading
Manufacturing
10 min read
Areas of Expertise :
Toxicology, Epidemiology, Environmental Science, Water Contamination, Toxic Exposure
Published Date:
Last Modified Date:
Jurisdiction:
Federal. Sixth Circuit
The In re E.I. du Pont de Nemours and Company C-8 Personal Injury Litigation (MDL No. 2433) was centralized in the Southern District of Ohio in April 2013 to manage thousands of lawsuits concerning exposure to C-8 (also called PFOA) released from DuPont’s Washington Works plant near Parkersburg, West Virginia. Water supplies in parts of Ohio and West Virginia were contaminated, leading to claims of serious health effects. These suits stemmed from the Leach class action (filed 2001, settlement approved 2005), which created a Science Panel of three independent epidemiologists to evaluate health outcomes among more than 69,000 residents. After seven years of study, the panel issued findings in 2011–2012 linking C-8 exposure to six diseases: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension/preeclampsia. Under the Leach Settlement Agreement, DuPont agreed not to contest general causation for these linked diseases, while individual plaintiffs still had to prove specific causation in their cases.
The MDL ultimately involved nearly 3,700 lawsuits and several jury trials. Key bellwether outcomes included Bartlett (kidney cancer; $1.6 million verdict) and Freeman (testicular cancer; $5.1 million compensatory and $0.5 million punitive). The first non-bellwether trial, Vigneron (testicular cancer), produced a $2 million compensatory verdict and a $10.5 million punitive award. In Abbott, a jury awarded $40 million to Travis Abbott and $10 million to Julie Abbott, though her award was reduced to $250,000 under the Ohio Tort Reform Act; the Sixth Circuit affirmed the verdicts in 2022. Settlements came in stages: DuPont announced a $670.7 million settlement-in-principle in February 2017, resolving about 3,500 cases, followed by a second settlement in 2021 and a final settlement in 2024 that closed 73 remaining claims. With no active cases pending, the court formally suggested dissolving MDL 2433 on February 12, 2025. Judicial Panel on Multidistrict Litigation orders in 2018 and 2022 confirmed continued coordination of related lawsuits. In the broader context of chemical accidents, the DuPont C-8 litigation is notable for its reliance on scientific findings, the use of bellwether trials to steer outcomes, and its step-by-step resolution through multiple settlement phases.
Residents living near DuPont’s Washington Works plant filed a lawsuit alleging that C-8 (PFOA) discharges had contaminated local water supplies in Ohio and West Virginia. The West Virginia court certified a mandatory class in 2002 covering about 80,000 residents across several affected water districts. This filing became the foundation for later federal multidistrict litigation.
The Leach Settlement required DuPont to fund a comprehensive epidemiological study and water treatment projects. A Science Panel of three independent epidemiologists was tasked with evaluating health impacts on more than 69,000 residents, and DuPont agreed not to dispute general causation for any disease the panel found linked to C-8 exposure. The agreement paused further lawsuits while the study was conducted.
After seven years of study, the Science Panel reported a Probable Link between C-8 exposure and six diseases: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension/preeclampsia. Class members with these diseases could pursue personal-injury suits, while claims based on other conditions were barred. These findings defined the scope of all subsequent litigation.
The Judicial Panel on Multidistrict Litigation consolidated thousands of lawsuits into In re E.I. du Pont de Nemours and Company C-8 Personal Injury Litigation (MDL No. 2433) in the Southern District of Ohio before Judge Edmund A. Sargus, Jr. Centralization streamlined discovery, coordinated rulings, and prepared the way for bellwether trials.
The first bellwether case, brought by Carla Bartlett for kidney cancer, went to trial. The jury awarded her $1.6 million in compensatory damages, establishing an early precedent for how the MDL would apply the Leach Agreement’s general-causation terms.
David Freeman’s testicular-cancer case became the second bellwether trial, with detailed court rulings on expert testimony. On July 6, 2016, the jury awarded $5.1 million in compensatory damages, followed by an additional $0.5 million in punitive damages on July 8, 2016. These verdicts further reinforced the viability of claims under the Leach framework.
Kenneth Vigneron’s testicular-cancer case was the first non-bellwether trial. The jury awarded $2 million in compensatory damages, and the court’s evidentiary orders confirmed consistent application of causation rules.
A few weeks after the compensatory verdict, the jury imposed $10.5 million in punitive damages against DuPont, further shaping settlement pressure in the MDL.
DuPont announced a $670.7 million settlement-in-principle resolving about 3,500 MDL cases. This marked the first major resolution phase following the initial bellwether verdicts.
Despite the large settlement, new cases were still being filed. The JPML ordered continued transfer of tag-along actions, noting that centralization remained necessary for consistency and efficiency.
Travis Abbott was awarded $40 million and his wife Julie Abbott $10 million for claims tied to testicular cancer and its consequences. Julie’s award was later reduced to $250,000 under the Ohio Tort Reform Act. The trial highlighted the application of collateral estoppel and the Leach Agreement to evidentiary rulings.
After the 2017 resolution, another settlement in 2021 resolved most of the remaining actions. Court filings note that this reduced the active docket substantially while residual claims proceeded.
The U.S. Court of Appeals for the Sixth Circuit affirmed the Abbott jury awards in full, rejecting DuPont’s arguments on collateral estoppel, evidentiary rulings, and statute-of-limitations defenses. This ruling solidified the MDL’s trial outcomes and interpretation of the Leach Agreement.
The JPML declined to end tag-along transfers, noting the MDL had included nearly 3,700 cases and five trials, with waves of settlements in 2017 and 2021. The Panel found continued centralization necessary for late-stage efficiency.
On the eve of a third trial phase, DuPont and plaintiffs agreed to settle the last 73 cases. This effectively closed the MDL’s active inventory.
With all cases resolved through settlements and completed appeals, Judge Edmund A. Sargus, Jr. granted a motion suggesting dissolution of MDL 2433. This confirmed the litigation’s closure, leaving the earlier jury verdicts and multi-phase settlements as the final outcomes.
Court:
United States District Court for the Southern District of Ohio
Case Name:
In re E. I. du Pont de Nemours and Company C-8 Personal Injury Litigation
Chemical Accidents
Chemical Exposures
Environmental Contamination
Groundwater Contamination
Environmental Toxicology
Carcinogenesis
Water Quality
Groundwater
The In re E.I. du Pont de Nemours and Company C-8 Personal Injury Litigation (MDL No. 2433) was centralized in the Southern District of Ohio in April 2013 to manage thousands of lawsuits concerning exposure to C-8 (also called PFOA) released from DuPont’s Washington Works plant near Parkersburg, West Virginia. Water supplies in parts of Ohio and West Virginia were contaminated, leading to claims of serious health effects. These suits stemmed from the Leach class action (filed 2001, settlement approved 2005), which created a Science Panel of three independent epidemiologists to evaluate health outcomes among more than 69,000 residents. After seven years of study, the panel issued findings in 2011–2012 linking C-8 exposure to six diseases: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension/preeclampsia. Under the Leach Settlement Agreement, DuPont agreed not to contest general causation for these linked diseases, while individual plaintiffs still had to prove specific causation in their cases.
The MDL ultimately involved nearly 3,700 lawsuits and several jury trials. Key bellwether outcomes included Bartlett (kidney cancer; $1.6 million verdict) and Freeman (testicular cancer; $5.1 million compensatory and $0.5 million punitive). The first non-bellwether trial, Vigneron (testicular cancer), produced a $2 million compensatory verdict and a $10.5 million punitive award. In Abbott, a jury awarded $40 million to Travis Abbott and $10 million to Julie Abbott, though her award was reduced to $250,000 under the Ohio Tort Reform Act; the Sixth Circuit affirmed the verdicts in 2022. Settlements came in stages: DuPont announced a $670.7 million settlement-in-principle in February 2017, resolving about 3,500 cases, followed by a second settlement in 2021 and a final settlement in 2024 that closed 73 remaining claims. With no active cases pending, the court formally suggested dissolving MDL 2433 on February 12, 2025. Judicial Panel on Multidistrict Litigation orders in 2018 and 2022 confirmed continued coordination of related lawsuits. In the broader context of chemical accidents, the DuPont C-8 litigation is notable for its reliance on scientific findings, the use of bellwether trials to steer outcomes, and its step-by-step resolution through multiple settlement phases.
Residents living near DuPont’s Washington Works plant filed a lawsuit alleging that C-8 (PFOA) discharges had contaminated local water supplies in Ohio and West Virginia. The West Virginia court certified a mandatory class in 2002 covering about 80,000 residents across several affected water districts. This filing became the foundation for later federal multidistrict litigation.
The Leach Settlement required DuPont to fund a comprehensive epidemiological study and water treatment projects. A Science Panel of three independent epidemiologists was tasked with evaluating health impacts on more than 69,000 residents, and DuPont agreed not to dispute general causation for any disease the panel found linked to C-8 exposure. The agreement paused further lawsuits while the study was conducted.
After seven years of study, the Science Panel reported a Probable Link between C-8 exposure and six diseases: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension/preeclampsia. Class members with these diseases could pursue personal-injury suits, while claims based on other conditions were barred. These findings defined the scope of all subsequent litigation.
The Judicial Panel on Multidistrict Litigation consolidated thousands of lawsuits into In re E.I. du Pont de Nemours and Company C-8 Personal Injury Litigation (MDL No. 2433) in the Southern District of Ohio before Judge Edmund A. Sargus, Jr. Centralization streamlined discovery, coordinated rulings, and prepared the way for bellwether trials.
The first bellwether case, brought by Carla Bartlett for kidney cancer, went to trial. The jury awarded her $1.6 million in compensatory damages, establishing an early precedent for how the MDL would apply the Leach Agreement’s general-causation terms.
David Freeman’s testicular-cancer case became the second bellwether trial, with detailed court rulings on expert testimony. On July 6, 2016, the jury awarded $5.1 million in compensatory damages, followed by an additional $0.5 million in punitive damages on July 8, 2016. These verdicts further reinforced the viability of claims under the Leach framework.
Kenneth Vigneron’s testicular-cancer case was the first non-bellwether trial. The jury awarded $2 million in compensatory damages, and the court’s evidentiary orders confirmed consistent application of causation rules.
A few weeks after the compensatory verdict, the jury imposed $10.5 million in punitive damages against DuPont, further shaping settlement pressure in the MDL.
DuPont announced a $670.7 million settlement-in-principle resolving about 3,500 MDL cases. This marked the first major resolution phase following the initial bellwether verdicts.
Despite the large settlement, new cases were still being filed. The JPML ordered continued transfer of tag-along actions, noting that centralization remained necessary for consistency and efficiency.
Travis Abbott was awarded $40 million and his wife Julie Abbott $10 million for claims tied to testicular cancer and its consequences. Julie’s award was later reduced to $250,000 under the Ohio Tort Reform Act. The trial highlighted the application of collateral estoppel and the Leach Agreement to evidentiary rulings.
After the 2017 resolution, another settlement in 2021 resolved most of the remaining actions. Court filings note that this reduced the active docket substantially while residual claims proceeded.
The U.S. Court of Appeals for the Sixth Circuit affirmed the Abbott jury awards in full, rejecting DuPont’s arguments on collateral estoppel, evidentiary rulings, and statute-of-limitations defenses. This ruling solidified the MDL’s trial outcomes and interpretation of the Leach Agreement.
The JPML declined to end tag-along transfers, noting the MDL had included nearly 3,700 cases and five trials, with waves of settlements in 2017 and 2021. The Panel found continued centralization necessary for late-stage efficiency.
On the eve of a third trial phase, DuPont and plaintiffs agreed to settle the last 73 cases. This effectively closed the MDL’s active inventory.
With all cases resolved through settlements and completed appeals, Judge Edmund A. Sargus, Jr. granted a motion suggesting dissolution of MDL 2433. This confirmed the litigation’s closure, leaving the earlier jury verdicts and multi-phase settlements as the final outcomes.
Oncology and Urology Expert Witnesses
Epidemiology Expert Witness
Toxicology Expert Witness
Environmental Science Expert Witness
Chemical Accidents Expert Witness
Industrial Hygiene Expert Witness
Leveraging Class Action Settlements to Shape Future Litigation
The Leach Settlement of 2005 created a Science Panel whose findings became binding on subsequent cases. This structure limited disputes over general causation and allowed plaintiffs to focus on specific causation and damages. Attorneys can study how settlement frameworks influence the trajectory of later multidistrict litigation.
The Role of Epidemiology in Establishing Causation
The Science Panel’s seven-year study of more than 69,000 residents produced Probable Link findings that determined which diseases could be litigated. This highlights how epidemiological evidence can shift litigation strategy by narrowing contested issues. Counsel should consider how court-approved scientific studies can be used to streamline future toxic tort cases.
Importance of Bellwether Trials in Multidistrict Litigation
Early bellwether cases such as Bartlett and Freeman set the tone for negotiations and jury perception of damages. These verdicts provided valuable data points that influenced settlement decisions. The subsequent non-bellwether Vigneron trial also reinforced jury willingness to award both compensatory and punitive damages, further shaping settlement pressure in the MDL.
Appellate Guidance on Collateral Estoppel and Evidentiary Rulings
The Sixth Circuit’s 2022 affirmance in Abbott clarified the application of collateral estoppel and upheld trial-level evidentiary rulings tied to the Leach Agreement. This appellate decision reinforced the weight of prior findings and jury verdicts. Practitioners should note how appellate courts handle consistency across thousands of related cases.
Multi-Phase Settlements as a Path to Final Resolution
Global settlements in 2017, 2021, and 2024 resolved nearly 3,700 lawsuits, culminating in the dissolution of the MDL in 2025. Each settlement phase reduced litigation risk while providing structured compensation to claimants. Attorneys may view phased settlements as a practical tool for resolving complex environmental and toxic exposure disputes.
The DuPont C-8/PFOA litigation demonstrates how long-running environmental exposure disputes can evolve from a single class action into one of the most extensive multidistrict proceedings in the United States. Beginning with the 2001 Leach case and the 2005 settlement that established the Science Panel, the litigation moved through years of scientific study, bellwether trials, appellate review, and staged settlements. By February 2025, the court confirmed that nearly 3,700 cases had been resolved through verdicts and settlements, closing one of the most significant toxic tort MDLs in recent decades.
In the broader context of chemical accidents, the case underscores the value of combining scientific evidence, coordinated litigation strategies, and phased resolutions to address widespread contamination. The binding Probable Link findings from the Science Panel streamlined thousands of claims and set the framework for how causation would be treated across the MDL. For attorneys, policymakers, and affected communities, the DuPont C-8/PFOA litigation highlights the importance of structured scientific inquiry, consistent rulings, and comprehensive settlement design in achieving resolution in complex environmental exposure disputes.
What was the DuPont C-8/PFOA litigation about?
The litigation centered on claims that DuPont’s Washington Works plant released C-8 (PFOA) into local drinking water supplies in Ohio and West Virginia. Residents alleged exposure caused serious health problems, leading to thousands of lawsuits consolidated in federal multidistrict litigation.
When did the DuPont C-8 lawsuits begin?
The first major case was the Leach class action, filed in 2001 and settled in 2005. The settlement created a Science Panel to study health effects, which later guided the multidistrict litigation centralized in April 2013.
What diseases were linked to C-8 exposure in this litigation?
The Science Panel found a Probable Link between C-8 exposure and six conditions: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension/preeclampsia. Only these diseases could be pursued in subsequent personal injury claims.
How much was the DuPont C-8 settlement?
DuPont reached a $670.7 million settlement in February 2017 that resolved about 3,500 cases. Additional settlements in 2021 and 2024 resolved the remaining lawsuits, closing nearly 3,700 claims in total.
What were the outcomes of the bellwether trials?
Early bellwether trials resulted in jury awards of $1.6 million in Bartlett and $5.1 million in Freeman, along with an additional $0.5 million in punitive damages. In Abbott, the jury awarded $40 million to Travis Abbott and $10 million to Julie Abbott, though her award was reduced to $250,000 under Ohio law.
When was the DuPont C-8 litigation fully resolved?
Oncology and Urology Expert Witnesses
Epidemiology Expert Witness
Toxicology Expert Witness
Environmental Science Expert Witness
Chemical Accidents Expert Witness
Industrial Hygiene Expert Witness
Leveraging Class Action Settlements to Shape Future Litigation
The Leach Settlement of 2005 created a Science Panel whose findings became binding on subsequent cases. This structure limited disputes over general causation and allowed plaintiffs to focus on specific causation and damages. Attorneys can study how settlement frameworks influence the trajectory of later multidistrict litigation.
The Role of Epidemiology in Establishing Causation
The Science Panel’s seven-year study of more than 69,000 residents produced Probable Link findings that determined which diseases could be litigated. This highlights how epidemiological evidence can shift litigation strategy by narrowing contested issues. Counsel should consider how court-approved scientific studies can be used to streamline future toxic tort cases.
Importance of Bellwether Trials in Multidistrict Litigation
Early bellwether cases such as Bartlett and Freeman set the tone for negotiations and jury perception of damages. These verdicts provided valuable data points that influenced settlement decisions. The subsequent non-bellwether Vigneron trial also reinforced jury willingness to award both compensatory and punitive damages, further shaping settlement pressure in the MDL.
Appellate Guidance on Collateral Estoppel and Evidentiary Rulings
The Sixth Circuit’s 2022 affirmance in Abbott clarified the application of collateral estoppel and upheld trial-level evidentiary rulings tied to the Leach Agreement. This appellate decision reinforced the weight of prior findings and jury verdicts. Practitioners should note how appellate courts handle consistency across thousands of related cases.
Multi-Phase Settlements as a Path to Final Resolution
Global settlements in 2017, 2021, and 2024 resolved nearly 3,700 lawsuits, culminating in the dissolution of the MDL in 2025. Each settlement phase reduced litigation risk while providing structured compensation to claimants. Attorneys may view phased settlements as a practical tool for resolving complex environmental and toxic exposure disputes.
The DuPont C-8/PFOA litigation demonstrates how long-running environmental exposure disputes can evolve from a single class action into one of the most extensive multidistrict proceedings in the United States. Beginning with the 2001 Leach case and the 2005 settlement that established the Science Panel, the litigation moved through years of scientific study, bellwether trials, appellate review, and staged settlements. By February 2025, the court confirmed that nearly 3,700 cases had been resolved through verdicts and settlements, closing one of the most significant toxic tort MDLs in recent decades.
In the broader context of chemical accidents, the case underscores the value of combining scientific evidence, coordinated litigation strategies, and phased resolutions to address widespread contamination. The binding Probable Link findings from the Science Panel streamlined thousands of claims and set the framework for how causation would be treated across the MDL. For attorneys, policymakers, and affected communities, the DuPont C-8/PFOA litigation highlights the importance of structured scientific inquiry, consistent rulings, and comprehensive settlement design in achieving resolution in complex environmental exposure disputes.
What was the DuPont C-8/PFOA litigation about?
The litigation centered on claims that DuPont’s Washington Works plant released C-8 (PFOA) into local drinking water supplies in Ohio and West Virginia. Residents alleged exposure caused serious health problems, leading to thousands of lawsuits consolidated in federal multidistrict litigation.
When did the DuPont C-8 lawsuits begin?
The first major case was the Leach class action, filed in 2001 and settled in 2005. The settlement created a Science Panel to study health effects, which later guided the multidistrict litigation centralized in April 2013.
What diseases were linked to C-8 exposure in this litigation?
The Science Panel found a Probable Link between C-8 exposure and six conditions: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension/preeclampsia. Only these diseases could be pursued in subsequent personal injury claims.
How much was the DuPont C-8 settlement?
DuPont reached a $670.7 million settlement in February 2017 that resolved about 3,500 cases. Additional settlements in 2021 and 2024 resolved the remaining lawsuits, closing nearly 3,700 claims in total.
What were the outcomes of the bellwether trials?
Early bellwether trials resulted in jury awards of $1.6 million in Bartlett and $5.1 million in Freeman, along with an additional $0.5 million in punitive damages. In Abbott, the jury awarded $40 million to Travis Abbott and $10 million to Julie Abbott, though her award was reduced to $250,000 under Ohio law.
When was the DuPont C-8 litigation fully resolved?
The multidistrict litigation concluded after the final settlement in 2024 resolved the last 73 cases. On February 12, 2025, the court formally suggested dissolution of the MDL, confirming the end of the litigation.
Chemical Accidents
Chemical Exposures
Environmental Contamination
Groundwater Contamination
Environmental Toxicology
Carcinogenesis
Water Quality
Groundwater
Manufacturing
Metallurgy, +4
Manufacturing
Manufacturing, +4
Manufacturing
The multidistrict litigation concluded after the final settlement in 2024 resolved the last 73 cases. On February 12, 2025, the court formally suggested dissolution of the MDL, confirming the end of the litigation.